Revenue
2023
2024
2025
Caris Life Sciences, Inc. (CAI)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $812.0M | $412.3M | $306.1M |
| Research & development | $101.6M | $113.9M | $116.9M |
| Operating income | $45.1M | −$257.1M | −$319.6M |
| EBITDAderived | $67.7M | −$208.2M | −$270.6M |
| Net income | −$68.1M | −$281.9M | −$341.4M |
| Basic EPSper diluted share | -$3.22 | -$10.66 | -$13.24 |
| Diluted EPSper diluted share | -$3.22 | -$10.66 | -$13.24 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 | Vacirca Jeff LDirector | BuyCommon Stock | 31.1K | $16.15 | $501.5K | 49.7K |
| Dec 11, 2025Form 4 · 10b5-1 | Power Luke ThomasSee Remarks | SellCommon Stock | 1.4K | $27.16 | $38.0K | 99.6K |
| Dec 11, 2025Form 4 · 10b5-1 | Power Luke ThomasSee Remarks | SellCommon Stock | 60.9K | $26.56 | $1.62M | 101.0K |
| Nov 7, 2025Form 4 | Spetzler David BaxleyPresident | BuyCommon Stock | 400 | $23.85 | $9.5K | 460.8K |
| Nov 7, 2025Form 4 | Denton John RusselSee Remarks | BuyCommon Stock · indirect | 4.2K | $24.09 | $100.8K | 9.2K |